贝伐珠单抗联合尼拉帕利在复发性卵巢癌维持治疗中的疗效与安全性OA

Objective To evaluate the efficacy and safety of bevacizumab combined with niraparib in maintenance therapy for recurrent ovarian cancer.Methods A total of 112 patients with recurrent ovarian cancer treated at the Department of Gynecologic Oncology,Gansu Wuwei Cancer Hospital,from January 2020 to August 2024 were enrolled.Patients were randomly assigned in a 1∶1 ratio to an observation group or a control group using a computer-generated random number table.The foundation chemotherapy regimens were carboplatin+paclitaxel or gemcitabine+docetaxel.The control group received bevacizumab,while the observation group received niraparib in addition to the regimen of the control group.Clinical efficacy,changes in tumor marker levels,quality of life,and incidence of adverse reactions were compared between the two groups.Re-sults Among the 112 enrolled patients,110 completed follow-up and reached the treatment endpoint,with a follow-up rate of 98.2％(110/112).The last follow-up was on February 20,2025.The objective response rate(ORR)and disease control rate(DCR)in the observation group were 61.8％(34/55)and 90.9％(50/55),respectively,which were significantly higher than those in the control group[41.8％(23/55)and 76.4％(42/55)](x2=4.406,P=0.036;x2=4.251,P=0.039).The median pro-gression-free survival(PFS)in the observation group was 16 months(95％CI:11.95-21.06),and the median overall survival(OS)was 20 months(95％CI:12.97-25.03);in the control group,the median PFS and OS were 12 months(95％CI:9.11-14.89)and 16 months(95％CI:13.11-18.89),respectively(Log-rank x2=7.406,P=0.007;Log-rank x2=6.576,P=0.010).Se-rum levels of carbohydrate antigen 125(CA125)and human epididymis protein 4(HE4)decreased significantly in both groups during treatment,while scores for physical function,role function,emotional function,social function,and overall quality of life increased significantly(all P＜0.05).After 3 and 6 cycles of treatment,patients in the observation group had significantly lower serum CA125 and HE4 levels and significantly higher scores for the aforementioned quality-of-life domains compared with the control group(all P＜0.05).The overall incidence of adverse reactions in the observation group was 47.3％(26/55),which was not statistically significantly different from that in the control group[40.0％(22/55)](x2=0.591,P=0.442).Con-clusion The combination of bevacizumab and niraparib demonstrates superior disease control in patients with recurrent ovar-ian cancer,more significantly reduces tumor marker levels,and improves patients' quality of life,with a favorable clinical safety profile.